Pedro Rosa-Neto Selected Research

3- (6- methylpyridin- 2- ylethynyl)cyclohex- 2- enone- O- methyloxime

1/2021	Large-scale mGluR5 network abnormalities linked to epilepsy duration in focal cortical dysplasia.
1/2021	In vivo hippocampal cornu ammonis 1-3 glutamatergic abnormalities are associated with temporal lobe epilepsy surgery outcomes.
10/2016	Metabotropic Glutamate Receptor Type 5 (mGluR5) Cortical Abnormalities in Focal Cortical Dysplasia Identified In Vivo With [11C]ABP688 Positron-Emission Tomography (PET) Imaging.
4/2016	In vivo characterization of metabotropic glutamate receptor type 5 abnormalities in behavioral variant FTD.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pedro Rosa-Neto Research Topics

Disease

86	Alzheimer Disease (Alzheimer's Disease) 02/2022 - 09/2008
44	Cognitive Dysfunction 10/2022 - 01/2012
37	Dementia (Dementias) 02/2022 - 06/2012
10	Atrophy 02/2022 - 01/2016
7	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022 - 03/2014
6	Disease Progression 01/2022 - 12/2011
5	Frontotemporal Dementia (Semantic Dementia) 01/2022 - 03/2014
5	Neuroinflammatory Diseases 01/2022 - 01/2013
5	Neoplasms (Cancer) 01/2019 - 02/2015
4	Tauopathies 01/2022 - 03/2014
4	Parkinson Disease (Parkinson's Disease) 01/2022 - 01/2017
3	Pain (Aches) 01/2022 - 10/2009
3	Brain Diseases (Brain Disorder) 01/2022 - 01/2013
3	Gliosis 12/2021 - 12/2010
3	Temporal Lobe Epilepsy 01/2021 - 12/2013
3	Amyloid Plaque 12/2020 - 01/2016
3	Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome) 01/2020 - 03/2017
3	Amyloidosis 12/2017 - 12/2010
3	Memory Disorders (Memory Loss) 01/2013 - 09/2008
2	Acute Disseminated Encephalomyelitis (Postinfectious Encephalomyelitis) 01/2022 - 01/2021
2	Mitochondrial Diseases (Mitochondrial Disease) 01/2022 - 01/2021
2	COVID-19 01/2022 - 01/2021
2	Guillain-Barre Syndrome 01/2022 - 01/2021
2	Encephalitis (Encephalitis, Rasmussen) 01/2022 - 01/2021
2	Focal Cortical Dysplasia 01/2021 - 10/2016
2	Inflammation (Inflammations) 01/2021 - 01/2019
2	Fibrosis (Cirrhosis) 01/2011 - 12/2010
1	Intracranial Hypertension 01/2022
1	Fatal Familial Insomnia 01/2022
1	Necrosis 01/2022
1	Prion Diseases (Transmissible Spongiform Encephalopathies) 12/2021
1	Glucose Intolerance 01/2021
1	Lewy Body Disease (Lewy Body Dementia) 01/2020
1	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy) 01/2020
1	Corticobasal Degeneration 01/2020
1	Carcinogenesis 01/2019
1	Neurobehavioral Manifestations 11/2018

Drug/Important Bio-Agent (IBA)

54	Biomarkers (Surrogate Marker)IBA 02/2022 - 12/2011
53	Amyloid (Amyloid Fibrils)IBA 10/2022 - 09/2008
8	Amyloid beta-PeptidesIBA 02/2022 - 09/2008
8	AZD4694IBA 02/2022 - 01/2020
8	Proteins (Proteins, Gene)FDA Link 01/2022 - 09/2008
7	Cholinergic Agents (Cholinergics)IBA 11/2021 - 12/2010
6	Apolipoproteins E (ApoE)IBA 01/2022 - 01/2016
6	florbetapirIBA 10/2021 - 06/2017
5	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 12/2010
5	Biological ProductsIBA 01/2022 - 07/2014
5	7- (6- fluoropyridin- 3- yl)- 5H- pyrido(4,3- b)indoleIBA 10/2021 - 01/2020
5	Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)IBA 01/2021 - 12/2013
4	3- (6- methylpyridin- 2- ylethynyl)cyclohex- 2- enone- O- methyloximeIBA 01/2021 - 04/2016
3	Indicators and Reagents (Reagents)IBA 02/2022 - 07/2017
3	ApolipoproteinsIBA 01/2022 - 01/2020
3	Glial Fibrillary Acidic ProteinIBA 12/2021 - 01/2021
3	Pharmaceutical PreparationsIBA 01/2020 - 09/2014
3	Naproxen (Naprosyn)FDA LinkGeneric 06/2019 - 01/2015
3	Pioglitazone (Actos)FDA Link 01/2013 - 09/2008
2	N- (4'- fluorobutyrophenone)- 4- (4- chlorophenyl)pyridinium (HPP(+))IBA 01/2022 - 01/2021
2	FluorineIBA 11/2021 - 01/2020
2	fluoroethoxy-benzovesamicolIBA 11/2021 - 01/2013
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2021 - 01/2018
2	Retinaldehyde (Retinal)IBA 01/2019 - 01/2019
2	THK5351IBA 01/2019 - 03/2017
2	tau Proteins (tau Protein)IBA 06/2017 - 03/2014
2	Phosphotransferases (Kinase)IBA 01/2017 - 02/2015
2	TropomyosinIBA 01/2017 - 02/2015
2	LigandsIBA 07/2014 - 01/2013
2	AntioxidantsIBA 01/2011 - 09/2008
2	Dopamine (Intropin)FDA LinkGeneric 04/2005 - 09/2004
1	EpitopesIBA 02/2022
1	2- (4'- (methylamino)phenyl)- 6- hydroxybenzothiazole (Pittsburgh compound B)IBA 01/2022
1	NeurograninIBA 01/2022
1	CytokinesIBA 01/2022
1	InterleukinsIBA 01/2022
1	Apolipoproteins B (ApoB)IBA 01/2022
1	neuromelaninIBA 01/2022
1	alpha-SynucleinIBA 01/2022
1	Histone Deacetylases (Histone Deacetylase)IBA 01/2022
1	antineoplaston A10 (A 10)IBA 01/2022
1	Protein Isoforms (Isoforms)IBA 12/2021
1	CarbonIBA 12/2021
1	Amino Acids FDA Link 12/2021
1	Cell Adhesion MoleculesIBA 12/2021
1	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 01/2021
1	verubulinIBA 01/2021
1	RadiopharmaceuticalsIBA 01/2021
1	Interleukin-6 (Interleukin 6)IBA 01/2021
1	ioflupaneIBA 01/2020
1	Threonine (L-Threonine)FDA Link 01/2020
1	Toll-Like Receptor 4IBA 01/2019
1	Monoamine Oxidase (MAO)IBA 01/2019
1	rasagiline (Azilect)FDA Link 01/2019
1	Complement System Proteins (Complement)IBA 11/2018
1	Cytochrome P-450 CYP2C19IBA 02/2018
1	visininIBA 01/2018
1	Synaptosomal-Associated Protein 25IBA 01/2018
1	Chitinase-3-Like Protein 1IBA 01/2018

Therapy/Procedure

3	Therapeutics 11/2017 - 01/2013
2	Denervation 11/2021 - 01/2021
1	Deprescriptions 01/2020
1	Precision Medicine 01/2018